for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Samsung Biologics Co Ltd

207940.KS

Latest Trade

400,500.00KRW

Change

2,500.00(+0.63%)

Volume

36,774

Today's Range

398,000.00

 - 

403,000.00

52 Week Range

241,500.00

 - 

420,000.00

As of on the Korea Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
398,000.00
Open
398,000.00
Volume
36,774
3M AVG Volume
2.77
Today's High
403,000.00
Today's Low
398,000.00
52 Week High
420,000.00
52 Week Low
241,500.00
Shares Out (MIL)
66.17
Market Cap (MIL)
26,333,670.00
Forward P/E
733.08
Dividend (Yield %)
--

Next Event

Samsung Biologics Co Ltd at Nomura Korea All Access

Latest Developments

More

Samsung Biologics Q3 Operating Profit $20 Mln, Up 125.6% Year Ago

Samsung BioLogics: S.Korea's Supreme Court Upholds Appeals Court Ruling To Set Aside Regulator's Disciplinary Actions Against Co

FDA Approves Biosimilar To Humira

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Samsung Biologics Co Ltd

SAMSUNG BIOLOGICS Co., Ltd. is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, a contract manufacturing organization (CMO) mainly develops, manufactures antibody drugs, which are used for the treatment of cancer, autoimmune disease, diabetes and other diseases. It also provides services, such as cell line generation, process and analytical method development and analytical services. The Company distributes its products within domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

300, Songdo bio-daero, Yeonsu-gu

+82.32.4553114

https://www.samsungbiologics.com/

Executive Leadership

Tae Han Kim

President, Chief Executive Officer, Director

Dongjoong Kim

Chief Financial Officer, Director

Kyusung Lee

Executive Vice President

James Choi

Chief Information Officer, Assistant Managing Director

Gwang Hun Yoon

Vice President

Key Stats

2.09 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, KRW)

2016

0.3K

2017

0.5K

2018

0.5K

2019(E)

0.6K
EPS (KRW)

2016

-3,115.000

2017

-1,466.000

2018

3,387.000

2019(E)

542.914
Price To Earnings (TTM)
110.16
Price To Sales (TTM)
54.55
Price To Book (MRQ)
6.42
Price To Cash Flow (TTM)
74.32
Total Debt To Equity (MRQ)
20.02
LT Debt To Equity (MRQ)
11.15
Return on Investment (TTM)
4.67
Return on Equity (TTM)
3.63

Latest News

Latest News

South Korea watchdog says to appeal court move to suspend Samsung BioLogics' sanctions

South Korea's top financial regulator, the Financial Services Commission (FSC), said on Tuesday it will file an appeal against a court decision to suspend sanctions on Samsung BioLogics Co Ltd.

South Korean court suspends regulator's disciplinary action against Samsung BioLogics

A South Korean court has suspended the financial regulator's disciplinary action against Samsung BioLogics Co Ltd <207940.KS> for allegedly breaching accounting rules, an official at the Seoul Administrative Court said on Tuesday.

S.Korean court suspends regulator's disciplinary action against Samsung BioLogics

A South Korean court has suspended the financial regulator's disciplinary action against Samsung BioLogics Co Ltd over breach of accounting rules, an official at the Seoul Administrative Court said on Tuesday.

South Korean prosecutors raid Samsung BioLogics' office in accounting probe

Samsung BioLogics Co Ltd's <207940.KS> on Thursday said its head office has been raided by South Korean prosecutors as part of a criminal probe into alleged accounting fraud.

S.Korean prosecutors raid Samsung Biologics' office in accounting probe

South Korean prosecutors on Thursday raided Samsung Biologics Co Ltd's head office outside of Seoul as part of a probe into alleged accounting fraud, the company said.

UPDATE 1-Samsung BioLogics shares to remain listed, resume trade on Dec. 11

South Korea's main stock exchange has decided Samsung BioLogics Co Ltd is qualified to continue trading on the exchange and that the company's shares will resume trading on Tuesday, the bourse said on Monday.

Samsung BioLogics shares to remain listed, resume trade on Dec. 11

South Korea's main stock exchange has decided Samsung BioLogics Co Ltd is qualified to continue trading on the exchange and that the company's shares will resume trading on Tuesday, the bourse said on Monday.

Samsung BioLogics files administrative lawsuit against regulator

Samsung BioLogics Co Ltd <207940.KS> said on Wednesday it had filed an administrative lawsuit against South Korea's financial regulator over the watchdog's recent ruling on accounting violations.

Samsung BioLogics' listing under review after regulator says it breached accounting rules

South Korea's top financial regulator said Samsung BioLogics Co Ltd <207940.KS> had intentionally breached accounting rules ahead of its 2016 listing, leading to a suspension in trading of the biotech firm's shares and a review of its listing status.

S.Korea regulator says Samsung BioLogics intentionally breached accounting rules

South Korea's top financial regulator on Wednesday said it found Samsung BioLogics Co Ltd intentionally breached accounting rules in inflating the company's value ahead of its 2016 stock exchange listing.

Samsung BioLogics shares plunge over accounting concerns

Shares in Samsung BioLogics Co Ltd <207940.KS> plunged on Monday amid concerns about its accounting practices ahead of a meeting of regulators this week to review whether it has violated rules which could lead to its delisting.

Hanjin Shipping sells part of container ship business for $31 mln

South Korea's Hanjin Shipping Co Ltd said on Tuesday it decided to sell part of its container ship business to Korea Line Corp for 37 billion Korean won ($31.38 million).

Samsung BioLogics shares rally on debut as pharma stocks cheer Trump win

Shares in Samsung BioLogics Co <207940.KS>, Samsung Group's contract biotech drug manufacturing arm, rallied to rise 5 percent in their debut on Thursday, mirroring the sector's jump overnight after Donald Trump's U.S. presidential election.

S.Korea Samsung BioLogics shares open below IPO price

Shares in Samsung BioLogics Co Ltd , Samsung Group's contract biotech drug manufacturing arm, fell slightly from the initial public offering price in their market debut on Thursday morning.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up